Talis Biomedical (TLIS) Competitors

Cue Health (NASDAQ:HLTH) and Talis Biomedical (NASDAQ:TLIS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, community ranking, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Does the MarketBeat Community favor HLTH or TLIS?

Talis Biomedical received 8 more outperform votes than Cue Health when rated by MarketBeat users. Likewise, 37.50% of users gave Talis Biomedical an outperform vote while only 7.14% of users gave Cue Health an outperform vote.

Company	Underperform	Outperform
Cue Health	Outperform Votes 1 7.14%	Underperform Votes 13 92.86%
Talis Biomedical	Outperform Votes 9 37.50%	Underperform Votes 15 62.50%

Does the media favor HLTH or TLIS?

In the previous week, Cue Health had 1 more articles in the media than Talis Biomedical. MarketBeat recorded 1 mentions for Cue Health and 0 mentions for Talis Biomedical. Cue Health's average media sentiment score of 0.00 equaled Talis Biomedical'saverage media sentiment score.

Company	Overall Sentiment
Cue Health	Neutral
Talis Biomedical	Neutral

Is HLTH or TLIS more profitable?

Cue Health has a net margin of -526.48% compared to Talis Biomedical's net margin of -5,784.73%. Cue Health's return on equity of -67.82% beat Talis Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Health	-526.48%	-67.82%	-53.79%
Talis Biomedical	-5,784.73%	-79.74%	-57.16%

Do insiders and institutionals hold more shares of HLTH or TLIS?

45.5% of Cue Health shares are owned by institutional investors. Comparatively, 43.8% of Talis Biomedical shares are owned by institutional investors. 12.5% of Cue Health shares are owned by insiders. Comparatively, 46.0% of Talis Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has better valuation and earnings, HLTH or TLIS?

Talis Biomedical has lower revenue, but higher earnings than Cue Health. Talis Biomedical is trading at a lower price-to-earnings ratio than Cue Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Health	$70.94M	0.10	-$373.46M	-$2.44	-0.02
Talis Biomedical	$2.13M	1.45	-$62.01M	-$28.02	-0.06

Which has more risk and volatility, HLTH or TLIS?

Cue Health has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Talis Biomedical has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500.

Do analysts recommend HLTH or TLIS?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Health	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Talis Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Cue Health beats Talis Biomedical on 9 of the 15 factors compared between the two stocks.